The problem with the whole 'post a woman author you've read 5 books by' is how many women don't get a second book, let alone five.
Anyway, carry on.
25.02.2026 13:22
👍 2791
🔁 269
💬 480
📌 60
The problem with the whole 'post a woman author you've read 5 books by' is how many women don't get a second book, let alone five.
Anyway, carry on.
Incredibly grateful to hear a beautiful invited talk from Dr Camila Coelho @camilahcoelho.bsky.social from Mount Sinai, NY🗽, revealing the first monoclonal antibody protective against an orthopoxvirus, for developing drugs and vaccines against Mpox which urgently needs new therapies 💉✨ #lorneiandi
What an honor! Thank you very much @aai.org, and I can't wait to see everyone in Boston!
We have a new episode out!
Dr. @camilahcoelho.bsky.social from Icahn School of Medicine talks about her lab’s work on mpox and other emerging viruses, her approach to #mentorship, and how her MBA education helps her in science.
Listen now: bit.ly/43M7r4x
@sinaiimmuno.bsky.social
Check our new paper here!
👇🏼
Three monoclonal antibodies targeting the mpox virus protein A35 have shown strong protection against severe disease in laboratory and animal models, indicating potential for new therapeutic approaches. doi.org/g9zg4h
Human monoclonal antibodies targeting A35 protect from death caused by monkeypox virus @cellcellpress.bsky.social @carolilucas.bsky.social @vivianasimonlab.bsky.social @mschotsaert.bsky.social
www.cell.com/cell/fulltex...
It starts in 10 minutes!
Link below👇
isv-online.org/event/isv-au...
Exciting data from @camilahcoelho.bsky.social lab! Congratulations to the team!
New paper from the Coelho lab with a modest contribution from us:
Join us next Wednesday as we hear from the great work from the Ward lab!
4/ Structural studies revealed all 3 mAbs target a highly conserved epitope in the A35 dimer groove, shared across orthopoxviruses. This explains their breadth and potency.
7/ Together, our findings establish A35 as a critical therapeutic target for mpox and related orthopoxviruses, paving the way for next-generation antibody therapies and improved vaccines.
🚨New Paper in Cell 🧵🔎
Happy to share our work led by the @camilahcoelho.bsky.social, on mAbs against mpox.
We were very excited (and lucky!) to contribute to this collab. effort.
🦠“Human monoclonal antibodies targeting A35 protect from death caused by mpox”🦠
doi.org/10.1016/j.cell.2025.08.004
🙌 This work was a major collaboration with incredible colleagues across the US, and we’re grateful for Mount Sinai's support.
#Mpox #Antibodies #Immunology
[9/9]
💡 Translational highlight: In mpox patients, polyclonal antibodies targeting this same A35 groove were enriched and correlated with better outcomes (shorter symptoms, no hospitalization).
Vaccination with Jynneos or Dryvax did not induce these antibodies.
[8/9]
Structural studies revealed all these mAbs, despite very different binding loops, converge on the groove formed by the A35 dimer.
This region is highly conserved across orthopoxviruses and even the broader poxvirus family.
[7/9]
How do they work?
✔️ Direct viral neutralization
✔️ Fc functions (required for optimal protection)
[6/9]
Treatment worked at just ~5 mg/kg...that’s 10x lower than the antibody doses used during recent Ebola outbreaks.
Even at low concentrations, these mAbs were outstandingly potent.
[5/9]
✨ In collaboration with Ian Wilson, Bernie Moss, @carolilucas.bsky.social, @mschotsaert.bsky.social @vivianasimonlab.bsky.social, that’s exactly what we did!
We now have highly potent A35 human mAbs, in vitro and in vivo. They are protective both before and after mouse infection.
[4/9]
This led us to hypothesize: if we could map where strong anti-A35 antibodies bind (the epitope), we could uncover urgently needed therapeutics and reveal viral weak spots that vaccines could target.
[3/9]
💡 In 2023, our lab showed (PMID: 37475115) that people infected with mpox had unusually high antibody levels against A35, a surface protein of MPXV.
These antibodies neutralized the virus better than antibodies from people vaccinated with Jynneos or Dryvax.
[2/9]
🚨 New article! Our study "Human monoclonal antibodies protect against death caused by mpox" is now published:
👉 www.cell.com/cell/fulltex...
[1/9]
Join us next Wednesday as we hear from the great work from the Ward lab!
Such a great time at the #IUIS2025! Inspiring conferences by amazing scientists such as @belkaidlab.bsky.social @virusesimmunity.bsky.social @linterman.bsky.social. Also loved seeing rising stars like @camilahcoelho.bsky.social @marionbrunck.bsky.social. Thanks to James Allison for his lecture !! ❤️
Congratulations to former LJI trainee Dr. Camila Coelho (now at the Icahn School of Medicine at Mount Sinai)! 🎉
Dr. Coelho has been named a "Rising Star" by Union of Immunological Societies — an award for early-stage researchers who are revolutionizing the field! bit.ly/4mGyF3H #health #medicine
Thank you Juan and so wonderful meeting you!
